Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Multi-omics integration reveals molecular networks and regulators of psoriasis.

Zhao Y, Jhamb D, Shu L, Arneson D, Rajpal DK, Yang X.

BMC Syst Biol. 2019 Jan 14;13(1):8. doi: 10.1186/s12918-018-0671-x.

2.

Single cell molecular alterations reveal target cells and pathways of concussive brain injury.

Arneson D, Zhang G, Ying Z, Zhuang Y, Byun HR, Ahn IS, Gomez-Pinilla F, Yang X.

Nat Commun. 2018 Sep 25;9(1):3894. doi: 10.1038/s41467-018-06222-0.

3.

Shared mechanisms among neurodegenerative diseases: from genetic factors to gene networks.

Arneson D, Zhang Y, Yang X, Narayanan M.

J Genet. 2018 Jul;97(3):795-806. Review.

4.

Multidimensional Integrative Genomics Approaches to Dissecting Cardiovascular Disease.

Arneson D, Shu L, Tsai B, Barrere-Cain R, Sun C, Yang X.

Front Cardiovasc Med. 2017 Feb 27;4:8. doi: 10.3389/fcvm.2017.00008. eCollection 2017. Review.

5.

Mergeomics: a web server for identifying pathological pathways, networks, and key regulators via multidimensional data integration.

Arneson D, Bhattacharya A, Shu L, Mäkinen VP, Yang X.

BMC Genomics. 2016 Sep 9;17(1):722. doi: 10.1186/s12864-016-3057-8.

6.

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.

Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM.

Oncotarget. 2014 Sep 15;5(17):7936-44.

7.

The association of pseudoephedrine sales restrictions on emergency department urine drug screen results in Oklahoma.

Brandenburg MA, Brown SJ, Arneson WL, Arneson DL.

J Okla State Med Assoc. 2007 Nov;100(11):436-9.

PMID:
18183861
8.

Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane.

Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A.

Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2477-81.

9.

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.

Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D.

Clin Cancer Res. 2004 Aug 15;10(16):5403-17.

10.

A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.

Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA.

Clin Cancer Res. 2002 Oct;8(10):3105-17.

11.
12.

Application of microencapsulation technology to improve the stability of citral in rodent diets.

Kuhn GO, McCampbell P, Singmaster G, Arneson DW, Jameson CW.

Fundam Appl Toxicol. 1991 Oct;17(3):635-40.

PMID:
1794663
13.
14.

Toxicology studies of a chemical mixture of 25 groundwater contaminants. I. Chemistry development.

Yang RS, Goehl TJ, Brown RD, Chatham AT, Arneson DW, Buchanan RC, Harris RK.

Fundam Appl Toxicol. 1989 Oct;13(3):366-76.

PMID:
2612771
15.

Rapid determination of low pg/mg amounts of N-nitrosodimethylamine in rodent body fluid and tissue samples by low resolution mass spectrometry.

Timmons L, Brown R, Onstot J, Cannon M, Murrill E, Arneson D.

J Anal Toxicol. 1988 May-Jun;12(3):117-21.

PMID:
3386205
16.
17.

Strychnine therapy in nonketotic hyperglycinemia.

Arneson D, Ch'ien LT, Chance P, Wilroy RS.

Pediatrics. 1979 Mar;63(3):369-73.

PMID:
440838
18.

Glycine encephalopathy.

Ch'ien LT, Chance P, Arneson D, Wilroy RS, Ranu GS.

N Engl J Med. 1978 Mar 23;298(12):687. No abstract available.

PMID:
628392
19.

Quantitative analysis of plasma fibrin monomer.

Arneson D.

Thromb Res. 1976 Jan;8(1):31-41. No abstract available.

PMID:
1251340

Supplemental Content

Loading ...
Support Center